Bionime Corp (4737) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Bionime Corp stock TWD 10.60, price TWD 57.30, that is 81.5% below the price, quality 25 out of 100. Rating: strongly overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 47.45 TWD – 90.75 TWD · fair‑value band 4.22 TWD – 16.25 TWD · the 57.30 TWD price screens above the 10.60 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Bionime in your weekly email
Every Wednesday you see whether Bionime is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Belarus, Algeria, the United Arab Emirates, Egypt, and internationally.
Show moreShow less
The company manufactures and sells blood glucose meters and test strips to medical equipment companies, pharmacies, and hospitals, as well as offering blood glucose monitoring devices and systems under the RIGHTEST brand; a continuous glucose monitoring system under the iFree CGM brand; and medical blood glucose management systems.
It is also involved in the provision of biotechnology services; drug testing; examination of pharmaceutical products; and the sale of precision instruments. The company also provides wholesale medical devices, biotechnology services, pharmaceutical testing, and wholesale of precision instruments.
Bionime Corporation was incorporated in 2003 and is based in Taichung, Taiwan.
Stock analysis
Bionime Corp (4737) currently trades at 57.30 TWD, while our model-based Fair Value estimate is 10.60 TWD, 82% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 14.05 TWD per share, and 0 of the 7 models we run sit above the 57.30 TWD price.
Bear case: the Asset-Based group reads lowest at 7.16 TWD, and 7 of the 7 models stay below the price. Data coverage for this calculation is low.
Scenario range: 4.22 TWD (bear) to 16.25 TWD (bull), the price of 57.30 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Bionime Corp reported revenue of 1.8B TWD in FY2025 versus 1.8B TWD in FY2021, a compound −0.2%/yr. Reported net income was −180M TWD in FY2025.
Key figures
Market cap 4.5B TWD (≈ $137M) Micro · P/S ratio 2.70 · EPS (TTM) −4.06 TWD · Dividend yield 2.6% · Net margin −16.7% · Return on equity −14.2% · Return on assets (EBIT) −0.3% (5-year average) · Operating margin −12.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 20% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −82%, 4737 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (0.6000 TWD to 15.63 TWD). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear4.22 TWDFair Value 10.60 TWDBull16.25 TWD
Price 57.30 TWD · Downside -81.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF6.05 TWD12.93 TWD20.65 TWD78
Growth DCF6.27 TWD12.47 TWD19.12 TWD77
5Y Revenue Exit4.96 TWD15.19 TWD27.60 TWD68
All 7 models by family
DCF Models
FCF DCF6.05 TWD12.93 TWD20.65 TWD78
5Y Revenue Exit4.96 TWD15.19 TWD27.60 TWD68
10Y Revenue Exit4.76 TWD12.87 TWD22.60 TWD63
Multiples
EV/Revenuen/a0.6000 TWD>2.40 TWD50
Asset-Based
NCAV (Graham)5.34 TWD7.16 TWD10.69 TWD54
Growth DCF
Growth DCF6.27 TWD12.47 TWD19.12 TWD77
Rev-Margin DCF4.96 TWD15.63 TWD27.13 TWD68
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.33/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−4.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Start year 2020 (pandemic). Over 10 years: +1.3% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
4.6% (2020) → −10.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+28.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +26.8% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score25 · Bottom 25%
Fair Value upside−81.5% · Bottom 25%
Profitability
Return on assets−3.2% · Bottom 25%
Net margin (12 months)−16.7% · Bottom 25%
Operating margin (12 months)−12.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−9.6% · Bottom 25%
Dividend yield (12 months)2.6% · Above median
Balance sheet
Debt / equity1.07× · Highest 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/B2.58× · Pricier than median
P/S (12 months)2.62× · Pricier than median
Price / free cash flow (fiscal year)21.8× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 25
FUTURE (revenue growth)0· sector 40
PAST (return on equity)0· sector 30
HEALTH (low debt)47· sector 96
DIVIDEND (yield)53· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Bionime Corp Fair Value". https://www.fairvalue-calculator.com/stock/4737
Frequently asked questions
Is Bionime Corp (4737) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 10.60 TWD versus a price of 57.30 TWD, about 82% lower (overvalued).
What is the fair value of 4737?
Our model-based fair value for Bionime Corp is 10.60 TWD (as of Nov 8, 2026), built from audited fundamentals. The current price: 57.30 TWD.
What is the quality score of 4737?
Bionime Corp has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bionime Corp (4737)?
Our model-based price target is the fair value of 10.60 TWD (as of Nov 8, 2026) from 7 valuation models. Cautious scenario 4.22 TWD, optimistic scenario 16.25 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Bionime Corp stock forecast for 2026?
Our models put fair value at 10.60 TWD, about 82% lower versus a price of 57.30 TWD (overvalued). Cautious scenario 4.22 TWD, optimistic scenario 16.25 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Bionime Corp (4737)?
Bionime Corp reported trailing-twelve-month revenue of about 1.7B TWD (latest available figure, as of Nov 8, 2026).
Does Bionime Corp pay a dividend?
Bionime Corp currently shows a dividend yield of 2.63% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Bionime Corp (4737)?
Bionime Corp has a dividend yield of 2.6%.
What growth is priced into Bionime Corp (4737)?
For today's price to be fair in a discounted-cash-flow model, Bionime Corp would have to grow free cash flow by +28.8 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.0 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 4737 use?
Our models discount Bionime Corp at 13.3 %: a base by market capitalisation (micro), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bionime Corp that is +28.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has Bionime Corp (4737) delivered so far?
Over the past 5 years revenue at Bionime Corp grew +2.0 % a year. The price currently implies free-cash-flow growth of +28.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bionime Corp (4737) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Bionime Corp (+28.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bionime Corp (4737)?
The free-cash-flow yield on the price is 4.59 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow Bionime Corp produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bionime Corp (4737)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bionime Corp it is 10.60 TWD per share (as of Nov 8, 2026), against a price of 57.30 TWD. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Bionime Corp stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 4737 trades above its calculated fair value: price 57.30 TWD, fair value 10.60 TWD, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4737?
No. The price is what the market pays today (57.30 TWD); the fair value is what the company's own numbers justify (10.60 TWD). For Bionime Corp the two are 46.70 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Bionime Corp worth?
The market values Bionime Corp at about 4.5B TWD (market capitalisation, as of Nov 8, 2026). Per share that is 57.30 TWD; our models calculate a fair value of 10.60 TWD per share.
What do the bullish and bearish scenarios say about 4737?
Our models span a range for Bionime Corp: cautious scenario 4.22 TWD, base 10.60 TWD, optimistic 16.25 TWD per share (as of Nov 8, 2026, price 57.30 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Bionime Corp (4737)?
Balance-sheet figures for Bionime Corp (as of Nov 8, 2026): return on equity −14.2%, debt of 1.07 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is 4737 from its 52-week high?
Bionime Corp trades at 57.30 TWD, about 20% below its 52-week high of 71.70 TWD and 11% above the low of 51.50 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 10.60 TWD is for.
Which stocks are comparable to Bionime Corp?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bionime Corp stock attractive at the current price?
The data as of Nov 8, 2026: price 57.30 TWD, calculated fair value 10.60 TWD (−82%), Quality Score 25/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4737 calculated?
We run Bionime Corp through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of 10.60 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Bionime Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bionime Corp (4737)?
The closing price on Nov 9, 2026 was 57.30 TWD. Our model-based fair value is 10.60 TWD, about 82% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bionime Corp right now?
The price sits above even our optimistic bull case (16.25 TWD). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (4.22 TWD to 16.25 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Bionime Corp
How large is the market capitalisation of Bionime Corp (4737)?
The market capitalisation of Bionime Corp is 4.5B TWD (≈ $137M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bionime Corp (4737)?
The price-to-sales ratio of Bionime Corp is 2.70 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bionime Corp (4737)?
Earnings per share at Bionime Corp are −4.06 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bionime Corp (4737)?
The dividend yield of Bionime Corp is 2.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bionime Corp (4737)?
The net margin of Bionime Corp is −16.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bionime Corp (4737)?
The return on equity (ROE) of Bionime Corp is −14.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bionime Corp (4737)?
On an EBIT basis the return on assets of Bionime Corp is −0.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bionime Corp (4737)?
The operating margin of Bionime Corp is −12.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bionime Corp (4737)?
Revenue at Bionime Corp is growing −9.6% versus a year earlier (3y avg −6.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bionime Corp (4737)?
Earnings per share at Bionime Corp are growing −58.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Bionime Corp (4737) carry?
The net debt of Bionime Corp is 2.6B TWD (fiscal year 2025, ≈ 12.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bionime Corp in the live analysis
One click puts Bionime Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026